TGFB1 and cancer: NIS793 is a pan anti-TGFβ-neutralizing antibody that is currently being tested in a phase 2 clinical trial for patients with metastatic PDAC in combination with gemcitabine/nab-paclitaxel chemotherapy (NCT04390763).262 TβRI kinase inhibitors have also been combined with targeted therapies to overcome drug resistance in pre-clinical cancer models.